万基遗传 MYGN 深 沪
等待开盘 09-17 09:30:00 美东时间
7.50
+0.190
+2.60%
华盛通- 最 高7.65
- 今 开7.34
- 成交量 121.72万股
- 最 低 7.14
- 昨 收 7.31
- 总市值 6.98亿
- 52周最高 27.55
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.76
- 委 比 -62.17%
- 总股本 9304.46万
- 历史最高 50.44
- 量 比 0.71
- 振 幅 6.98%
- 历史最低 3.76
- 每 手 1
- 风险率 3.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
Myriad Genetics announced that The Lancet Oncology published a study highlighting the performance of its Precise MRD test in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). The study demonstrated that the test can detect circulating tumor DNA (ctDNA) levels in patients with very low tumor burden, potentially allowing patients to delay or avoid systemic treatments. Key findings include: 94% of patients tested at baseline had...
09-04 23:00
Myriad Genetics Publishes Meta-Analysis Of 3,532 MDD Patients Showing GeneSight Psychotropic Test Improves Response And Remission Rates Vs. Standard Treatment
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532
09-04 04:33
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
A new meta-analysis published in the *Journal of Clinical Psychopharmacology* highlights the benefits of Myriad Genetics' GeneSight Psychotropic test for patients with major depressive disorder (MDD). The study, which analyzed data from six prospective controlled trials involving 3,532 adults, found that patients whose treating clinicians had access to GeneSight test results were 41% more likely to achieve remission and 30% more likely to achieve...
09-03 20:30
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that its management will participate in two upcoming healthcare conferences: The Wells Fargo Healthcare Conference on Thursday, Sept. 4 at 3:45pm ET and The Morgan Stanley Annual Global Healthcare Conference on Wednesday, Sept. 10 at 7:45am ET. Links to live and archived webcasts are available at investor.myriad.com. Myriad Genetics is...
08-27 20:05
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
Two new studies highlight DecisionDx-SCC's superior performance in predicting local recurrence and metastasis risks for high-risk cutaneous squamous cell carcinoma (SCC) patients, surpassing current staging systems. The test also aligns with clinician treatment thresholds for adjuvant radiation therapy and surveillance imaging. Among 414 high-risk SCC patients, DecisionDx-SCC significantly stratified risk, showing progressively lower survival rat...
08-25 11:00
万基遗传达成合作推进癌症诊断技术的协议
美股周三早盘，基因检测与精准医疗公司万基遗传（Myriad Genetics，MYGN）股价下跌4.1%，此前有报道称该公司已与全球领先的液体活检公司AN...
08-20 22:51
ANGLE plc partners with Myriad Genetics to advance cancer diagnostics
ANGLE plc (OTCQX:ANPCF) and Myriad Genetics (NASDAQ:MYGN) have announced a new partnership to advance cancer diagnostics. The collaboration will use ANGLE's Parsortix® system to capture cancer cells f...
08-20 15:08
Myriad Genetics Appoints Ben R. Wheeler as CFO
Myriad Genetics ( ($MYGN) ) has issued an announcement. On August 18, 2025, Myr...
08-18 21:00
Myriad Genetics announces CFO appointment
Ben Wheeler appointed chief financial officer of Myriad Genetics (NASDAQ:MYGN), effective August 16, 2025. Wheeler has been with the company since 2011, most recently serving as CFO of Operations sinc...
08-18 20:43
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
Myriad Genetics announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Wheeler has been with the company since December 2011, holding various leadership roles. Scott Leffler, who has served as CFO since January 2024, will transition to a consulting role through September 2, 2025. The company reaffirmed its 2025 financial guidance.
08-18 12:30
